Tonix Pharmaceuticals (NASDAQ:TNXP)‘s stock had its “buy” rating restated by stock analysts at Aegis in a report released on Friday.

TNXP has been the subject of several other reports. ValuEngine upgraded shares of Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Dawson James reiterated a “buy” rating and set a $9.00 price objective on shares of Tonix Pharmaceuticals in a research report on Wednesday, August 23rd. Roth Capital upgraded shares of Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Friday, August 18th. They noted that the move was a valuation call. Finally, Drexel Hamilton started coverage on shares of Tonix Pharmaceuticals in a research report on Tuesday, August 22nd. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.33.

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) traded down $0.06 during trading hours on Friday, hitting $3.78. 48,097 shares of the stock traded hands, compared to its average volume of 344,198. Tonix Pharmaceuticals has a one year low of $2.85 and a one year high of $9.40.

A number of hedge funds have recently added to or reduced their stakes in TNXP. Oxford Asset Management acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth approximately $1,531,000. Millennium Management LLC grew its holdings in Tonix Pharmaceuticals by 17.0% during the 4th quarter. Millennium Management LLC now owns 911,928 shares of the company’s stock worth $6,994,000 after acquiring an additional 132,429 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Tonix Pharmaceuticals during the 1st quarter worth approximately $290,000. A.R.T. Advisors LLC bought a new stake in Tonix Pharmaceuticals during the 1st quarter worth approximately $117,000. Finally, Sabby Management LLC grew its holdings in Tonix Pharmaceuticals by 52.0% during the 2nd quarter. Sabby Management LLC now owns 585,914 shares of the company’s stock worth $1,166,000 after acquiring an additional 200,518 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/tonix-pharmaceuticals-tnxp-buy-rating-reaffirmed-at-aegis.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Analyst Recommendations for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.